Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases
Por:
Liu Z, Ezzedine N, Eterovic A, Ensor J, Huang H, Albanell J, Choi D, Lluch A, Liu Y, Rojo F, Wong H, Martinez-Duenas E, Guerrero-Zotano A, Shao Z, Darcourt J, Mills G, Dave B, Chang J
Publicada:
1 nov 2019
Resumen:
Purpose Limited knowledge exists on the detection of breast cancer stem cell (BCSC)-related mutations in circulating free DNA (cfDNA) from patients with advanced cancers. Identification of new cancer biomarkers may allow for earlier detection of disease progression and treatment strategy modifications. Methods We conducted a prospective study to determine the feasibility and prognostic utility of droplet digital polymerase chain reaction (ddPCR)-based BCSC gene mutation analysis of cfDNA in patients with breast cancer. Results Detection of quantitative BCSC gene mutation in cfDNA by ddPCR mirrors disease progression and thus may represent a valuable and cost-effective measure of tumor burden. We have previously shown that hematological and neurological expressed 1-like (HN1L), ribosomal protein L39 (RPL39), and myeloid leukemia factor 2 (MLF2) are novel targets for BCSC self-renewal, and targeting these genetic alterations could be useful for personalized genomic-based therapy. Conclusion BCSC mutation detection in cfDNA may have important implications for diagnosis, prognosis, and serial monitoring.
Filiaciones:
Liu Z:
Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 20032, Peoples R China
Houston Methodist Res Inst, Houston, TX 77030 USA
Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
Ezzedine N:
Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA
Univ Texas MD Anderson Canc Ctr, Inst Personalized Canc Therapy, Houston, TX 77030 USA
Eterovic A:
Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA
Univ Texas MD Anderson Canc Ctr, Inst Personalized Canc Therapy, Houston, TX 77030 USA
Ensor J:
Houston Methodist Canc Ctr, 6445 Main St P21-34, Houston, TX 77030 USA
Huang H:
Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Invest Canc Therapeut, Houston, TX 77030 USA
Albanell J:
GEICAM Spanish Breast Canc Grp, Madrid 28703, Spain
ISCIII, CIBERONC, Ctr Invest Biomed Red Oncol, Madrid 28029, Spain
Hosp del Mar, Barcelona 08003, Spain
Choi D:
Houston Methodist Res Inst, Houston, TX 77030 USA
Houston Methodist Canc Ctr, 6445 Main St P21-34, Houston, TX 77030 USA
Lluch A:
GEICAM Spanish Breast Canc Grp, Madrid 28703, Spain
ISCIII, CIBERONC, Ctr Invest Biomed Red Oncol, Madrid 28029, Spain
Hosp Clin Univ Valencia, Valencia 46010, Spain
Liu Y:
Houston Methodist Res Inst, Houston, TX 77030 USA
Houston Methodist Canc Ctr, 6445 Main St P21-34, Houston, TX 77030 USA
Rojo F:
GEICAM Spanish Breast Canc Grp, Madrid 28703, Spain
ISCIII, CIBERONC, Ctr Invest Biomed Red Oncol, Madrid 28029, Spain
Fdn Jimenez Diaz, E-28040 Madrid, Spain
Wong H:
Houston Methodist Res Inst, Houston, TX 77030 USA
Houston Methodist Canc Ctr, 6445 Main St P21-34, Houston, TX 77030 USA
Martinez-Duenas E:
GEICAM Spanish Breast Canc Grp, Madrid 28703, Spain
Hosp Prov Castellon, Castellon de La Plana 12002, Spain
Guerrero-Zotano A:
GEICAM Spanish Breast Canc Grp, Madrid 28703, Spain
Inst Valenciano Oncol, Valencia 46009, Spain
Shao Z:
Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 20032, Peoples R China
Darcourt J:
Houston Methodist Canc Ctr, 6445 Main St P21-34, Houston, TX 77030 USA
Mills G:
Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA
Univ Texas MD Anderson Canc Ctr, Inst Personalized Canc Therapy, Houston, TX 77030 USA
Dave B:
Houston Methodist Res Inst, Houston, TX 77030 USA
Houston Methodist Canc Ctr, 6445 Main St P21-34, Houston, TX 77030 USA
Chang J:
Houston Methodist Res Inst, Houston, TX 77030 USA
Houston Methodist Canc Ctr, 6445 Main St P21-34, Houston, TX 77030 USA
|